Chemomab Therapeutics Ltd. (CMMB) Fundamentals

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
SHARE INFORMATION
Market Cap$ 23,166,466
Shares Outstanding11,525,605
Float11,506,063
Percent Float99.83%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -1.18
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions29
Institutional Holdings Date2022-10-31
Institutional Bought Previous 3 Months4,936
Institutional Holdings Percent28.2%
Institutional Sold Previous 3 Months24,211
Insider Holdings Date2022-10-31
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned19,542
TRADING INFO
52 Week High$ 9.96
52 Week Low$ 1.75
52 Week High Change$ -76.30
21 Day Moving Average$ 2.0671
21 Day Extended Moving Average$ 2.0983
50 Day Moving Average$ 2.2295
50 Day Extended Moving Average$ 2.3047
200 Day Moving Average$ 3.2894
200 Day Extended Moving Average$ 4.3852
10 Day Average Volume156,380
20 Day Average Volume87,592
30 Day Average Volume64,376
50 Day Average Volume47,930
Alpha-0.070063
Beta0.6442
Standard Deviation0.226499
R20.025619
7 Day Price Change$ -0.27
7 Day Percent Change-11.84%
21 Day Price Change$ -0.03
21 Day Percent Change-1.47%
30 Day Price Change$ 0.01
30 Day Percent Change0.5%
Month to Date Price Change$ -0.025
Month to Date Percent Change-1.23%
Quarter to Date Price Change$ -0.48
Quarter to Date Percent Change-19.28%
180 Day Price Change$ -0.99
180 Day Percent Change-33.0%
200 Day Price Change$ -1.02
200 Day Percent Change-33.66%
Year to Date Price Change$ -4.89
Year to Date Percent Change-70.87%

Chemomab Therapeutics Ltd. (CMMB) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book0.50
Total Debt To Equity0.00
Int Coverage0.00
Current Ratio8.90
Leverage Ratio1.10
Quick Ratio8.90
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-1.00
Enterprise Value$ -23,170,790
Price to Sales0.00
Price to Free Cash-1.30
PE High Last 5 Years0.00
Price To Book0.50
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book0.50
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-45.48
Return on Equity-48.76
Return on Capital-44.09

Chemomab Therapeutics Ltd. (CMMB) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorSomekh Chaikin
CEODale R. Pfost
Emplyoees20
Last AuditUQ
CIK0001534248
IndustryBiotechnology
SectorHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)(541714)
CONTACT INFO
AddressKiryat Atidim
Building 7
Tel Aviv, 6158002
Websitehttps://www.chemomab.com
Facsimile-
Telephone+972 773310156
Email-


Your Recent History
NASDAQ
CMMB
Chemomab T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.